Veritas In Silico (TYO:130A) said its patent on its method for screening compounds for controlling RNA function, will be listed in the European Patent Bulletin on Jan. 1, 2025, according to its filing on Monday.
Originally registered in Japan in September 2020, this patent enhances the company's mRNA-targeted drug discovery technology.
Although it will have minimal immediate impact on business performance, the patent is crucial for Veritas In Silico's globalization and advancement of their ibVIS(r) drug discovery platform.
Veritas In Silico's shares jumped over 20%.
Price (JPY): $882.00, Change: $+150, Percent Change: +20.49%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.